Impax Laboratories (IPXL) Inactive 10-Q2015 Q1 Quarterly report

Filed: 11 May 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: add, Adrenaclick, Alameda, Alaska, Alaskan, Albendazole, Albenza, Albertson, amphetamine, approach, argument, arrive, Arthrotec, aspartate, assumed, assuming, beneficiary, blister, Blue, calcipotriene, captive, carbon, CD, civilian, closingof, Code, commodity, confirm, contributory, covenant, coverage, cream, declared, defendant, Defense, Department, description, detail, detailed, dextroamphetamine, Diclofenac, distributor, Ditropan, drawn, Effexor, EMA, entry, epinephrine, ERISA, explanation, facilitiesimpose, Facilitiesto, foregoing, forma, formula, gap, Gel, governmental, grand, Griseofulvin, Grocery, guarantee, guaranteed, guaranteeing, HEB, herpetic, history, Horsham, incremental, Indemnity, inflation, inflationary, Interbank, intoxication, invasive, ix, jury, Justice, Kim, King, Kruger, larger, legacy, lien, lock, London, Louisiana, Mahaffay, maintenance, Mallinckrodt, manganese, master, mebendazole, Metadate, methodology, methylphenidate, Micro, Middle, Middlesex, military, Misoprostol, monoxide, monthly, Mountain, occurrence, officially, party, pharmacy, point, post, pre, preliminarily, premature, prepayment, priority, pro, prohibited, properly, purport, purpose, rationalization, redemption, redeployment, registered, regularly, reinvestment, relevant, removed, renamed, repay, repayment, responded, restructuring, RiconPharma, Rite, Roundtable, saccharate, Safeway, script, Shield, short, significantly, Skelaxin, smallest, solution, step, stream, structure, tapeworm, technique, terbutaline, thereto, thereunder, ticking, track, Trail, trailing, training, trend, unamortized, unfavorable, unutilized, VAI, vii, viii, voluntarily, Voluntary, Walgreen, withdrawn, XL

Removed: Abbreviated, acceleration, affirmative, Alternate, appeal, appointed, AstraZenecaUK, brought, category, Chilcott, circuit, claim, claimed, compare, cumulative, cure, decided, denominated, Dexilant, Dexlansoprazole, differentiated, diminution, discontinued, dismissal, disposal, EBITDA, enforcement, entitling, exact, exclusion, expiring, extend, Fesoterodine, flat, Fumarate, fundamental, Glaxo, GSK, hearing, Hsu, important, inaccuracy, inexperience, infringed, insolvency, involvement, jurisdiction, Larry, lawful, letterrelated, link, managing, monitor, nature, niche, NOL, North, objective, offsetting, ofother, ourdependence, owe, PDUFA, personal, pipeline, platformsand, pledge, pledged, preceding, President, pretax, productsafter, promotional, prospective, Publicly, qualitative, quantitative, ready, recoded, recognizerevenue, remained, renvela, repurchase, resubmitted, retire, retired, Risedronate, ruled, ruling, separation, site, software, stayed, stipulation, subsequent, supportive, symptomatic, Takeda, technical, terminating, thereon, Toviaz, translation, undergo, undrawn, unprofitable, User, validity, Vice, Warner, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IPXL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Impax Laboratories, Inc. (the “Company”) for the fiscal quarter ended March 31, 2015 (the “Report”), Bryan M. Reasons, Chief Financial Officer, and Senior Vice President, Finance hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code), that:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 11, 2015	By:	/s/ Bryan M. Reasons
		Bryan M. Reasons
		Chief Financial Officer and Senior VicePresident, Finance

The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code) and is not being filed as part of the Report or as a separate disclosure document.